Customise results display
Results 1-6 of 6 (Search time: 0.035 seconds).
|1-Sep-2018||Selecting antithrombotic therapy for stroke prevention in atrial fibrillation: Health professionals’ feedback on a decision support tool||Wang, Y; Bajorek, B|
|1-Feb-2018||Contemporary utilization of antithrombotic therapy for stroke prevention in patients with atrial fibrillation: an audit in an Australian hospital setting||Pandya, EY; Anderson, E; Chow, C; Wang, Y; Bajorek, B|
|1-Jan-2018||Impact of a computerized antithrombotic risk assessment tool on the prescription of thromboprophylaxis in Atrial Fibrillation: Hospital Setting||Pandya, E; Masood, N; Wang, Y; Krass, I; Bajorek, B|
|1-Jan-2017||Pilot of a computerised antithrombotic risk assessment tool version 2 (CARATV2.0) for stroke prevention in atrial fibrillation||Wang, Y; Bajorek, B|
|1-Dec-2016||Clinical pre-test of a computerised antithrombotic risk assessment tool for stroke prevention in atrial fibrillation patients: giving consideration to NOACs||Wang, Y; Bajorek, B|
|1-Apr-2016||Old age, high risk medication, polypharmacy: A ‘trilogy’ of risks in older patients with atrial fibrillation||Wang, Y; Singh, S; Bajorek, B|